Second round of drug prices negotiated under the IRA revealed
The pharma industry has called the IRA “price setting” and argues that negotiations have not cut out-of-pocket costs for patients.
Pricing and Market Access
Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase
Slow progress as rare disease regulations in developing ASEAN states begin to take shape
Questions on how new IRA drug prices will affect MFN agreements
Sri Lanka’s drug pricing reform: balancing affordability with sustainability
The threshold debate in Norway
Trump administration announces MFN drug pricing deal with Pfizer
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
